{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:49:24Z","timestamp":1782485364863,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:00:00Z","timestamp":1768003200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-026-05003-9","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T04:14:55Z","timestamp":1768018495000},"page":"2545-2552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term trends in androgen-directed therapy in advanced prostate cancer: a 29-year national analysis"],"prefix":"10.1007","volume":"58","author":[{"given":"Kieran","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilda M. H.","family":"Newton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon L.","family":"Perera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,10]]},"reference":[{"issue":"2","key":"5003_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla P (2019) Epidemiology of prostate cancer. World J Oncol 10(2):63\u201389","journal-title":"World J Oncol"},{"issue":"1","key":"5003_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","volume":"22","author":"ED Crawford","year":"2019","unstructured":"Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A et al (2019) Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis 22(1):24\u201338","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"12","key":"5003_CR3","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","volume":"15","author":"PA Watson","year":"2015","unstructured":"Watson PA, Arora VK, Sawyers CL (2015) Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer 15(12):701\u2013711","journal-title":"Nat Rev Cancer"},{"issue":"15","key":"5003_CR4","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1002\/cncr.24395","volume":"115","author":"H Akaza","year":"2009","unstructured":"Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S et al (2009) Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer 115(15):3437\u20133445","journal-title":"Cancer"},{"issue":"2","key":"5003_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/bju.13123","volume":"117","author":"J Schalken","year":"2016","unstructured":"Schalken J, Fitzpatrick JM (2016) Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int 117(2):215\u2013225","journal-title":"BJU Int"},{"issue":"4","key":"5003_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352\u2013360","journal-title":"N Engl J Med"},{"issue":"21","key":"5003_CR7","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","volume":"364","author":"JS de Bono","year":"2011","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21):1995\u20132005","journal-title":"N Engl J Med"},{"issue":"13","key":"5003_CR8","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367(13):1187\u20131197","journal-title":"N Engl J Med"},{"issue":"5","key":"5003_CR9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371(5):424\u2013433","journal-title":"N Engl J Med"},{"issue":"15","key":"5003_CR10","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"N Engl J Med"},{"issue":"26","key":"5003_CR11","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","volume":"378","author":"M Hussain","year":"2018","unstructured":"Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U et al (2018) Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 378(26):2465\u20132474","journal-title":"N Engl J Med"},{"issue":"13","key":"5003_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","volume":"380","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S et al (2019) Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380(13):1235\u20131246","journal-title":"N Engl J Med"},{"issue":"20","key":"5003_CR13","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39(20):2294\u20132303","journal-title":"J Clin Oncol"},{"issue":"1","key":"5003_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med 381(1):13\u201324","journal-title":"N Engl J Med"},{"issue":"23","key":"5003_CR15","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF et al (2020) Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 382(23):2197\u20132206","journal-title":"N Engl J Med"},{"key":"5003_CR16","unstructured":"Australian Bureau of Statistics (2025) Population clock and pyramid. https:\/\/www.abs.gov.au\/statistics\/people\/population\/population-clock-pyramid."},{"key":"5003_CR17","unstructured":"Department of Health Disability and Ageing (2026) Fees, Patient Contributions and Safety Net Thresholds. https:\/\/www.pbs.gov.au\/info\/healthpro\/explanatory-notes\/front\/fee?utm_source=chatgpt.com."},{"issue":"5","key":"5003_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/UPJ.0000000000000421","volume":"10","author":"B Pockros","year":"2023","unstructured":"Pockros B, Shabet C, Stensland K, Herrel L (2023) Out-of-pocket costs for prostate cancer medications substantially vary by Medicare part D plan: an online tool presents an opportunity to mitigate financial toxicity. Urol Pract 10(5):467\u2013475","journal-title":"Urol Pract"},{"issue":"9","key":"5003_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.31475","volume":"5","author":"A Gupta","year":"2022","unstructured":"Gupta A, Antonarakis ES, Blaes AH, Booth CM, Dusetzina SB (2022) Evaluation of Medicare coverage and estimated out-of-pocket costs for generic abiraterone products. JAMA Netw Open 5(9):e2231475","journal-title":"JAMA Netw Open"},{"issue":"1","key":"5003_CR20","doi-asserted-by":"publisher","first-page":"102","DOI":"10.36469\/jheor.2023.75208","volume":"10","author":"G Bencina","year":"2023","unstructured":"Bencina G, Petrova E, Sonmez D, Matos Pereira S, Dimitriadis I, Salomonsson S (2023) HTA and reimbursement status of metastatic hormone\u2011sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, and metastatic castration-resistant prostate cancer treatments in Europe: a patient access landscape review. J Health Econ Outcomes Res 10(1):102\u2013110","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"5003_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.juro.2009.02.141","volume":"182","author":"SL Chang","year":"2009","unstructured":"Chang SL, Liao JC, Shinghal R (2009) Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is independent of reimbursement changes: a Medicare and Veterans Health Administration claims analysis. J Urol 182(1):255\u2013261","journal-title":"J Urol"},{"issue":"14","key":"5003_CR22","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/fon-2023-0814","volume":"20","author":"PJ Goebell","year":"2024","unstructured":"Goebell PJ, Raina R, Chen S, Rege S, Shah R, Grossman JP et al (2024) Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia. Future Oncol 20(14):903\u2013918","journal-title":"Future Oncol"},{"issue":"6","key":"5003_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.14740\/wjon1476","volume":"13","author":"MS Fontes","year":"2022","unstructured":"Fontes MS, Schutz FA, de Almeida Luz M, Bomfim G, Saturnino LTM, Goncalves SC et al (2022) Treatment patterns among patients with advanced prostate cancer in Brazil: an analysis of a private healthcare system database. World J Oncol 13(6):350\u2013358","journal-title":"World J Oncol"},{"issue":"32","key":"5003_CR24","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A et al (2019) ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol 37(32):2974\u20132986","journal-title":"J Clin Oncol"},{"issue":"12","key":"5003_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED et al (2022) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386(12):1132\u20131142","journal-title":"N Engl J Med"},{"issue":"17","key":"5003_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71176","volume":"14","author":"B Zhou","year":"2025","unstructured":"Zhou B, Raval AD, Zhang Y, Korn MJ, Sambamoorthi N, Rasu R et al (2025) Treatment landscape for older men with metastatic hormone-sensitive prostate cancer in the United States. Cancer Med 14(17):e71176","journal-title":"Cancer Med"},{"key":"5003_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040240","author":"V Litvin","year":"2025","unstructured":"Litvin V, Aprikian AG, Dragomir A (2025) Cost-effectiveness analysis of contemporary advanced prostate cancer treatment sequences. Curr Oncol. https:\/\/doi.org\/10.3390\/curroncol32040240","journal-title":"Curr Oncol"},{"key":"5003_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-025-01000-8","author":"SJ Freedland","year":"2025","unstructured":"Freedland SJ, Hong A, El-Chaar N, De Hoedt AM, Kim J, Evans C et al (2025) Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer. Prostate Cancer Prostatic Dis. https:\/\/doi.org\/10.1038\/s41391-025-01000-8","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"11","key":"5003_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yekeduz E, Kaymakcalan MD, McKay RR, Gillessen S et al (2024) Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open 9(11):103736","journal-title":"ESMO Open"},{"issue":"9","key":"5003_CR30","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1158\/1078-0432.CCR-16-1357","volume":"23","author":"B Montgomery","year":"2017","unstructured":"Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ et al (2017) Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res 23(9):2169\u20132176","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5003_CR31","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.euo.2024.02.005","volume":"7","author":"J Xie","year":"2024","unstructured":"Xie J, Guo H, Dong B, Chen W, Jin C, Xu Q et al (2024) Olaparib combined with abiraterone versus olaparib monotherapy for patients with metastatic castration-resistant prostate cancer progressing after abiraterone and harboring DNA damage repair deficiency: a multicenter real-world study. Eur Urol Oncol 7(5):1088\u20131096","journal-title":"Eur Urol Oncol"},{"key":"5003_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2022.102159","volume":"78","author":"Q Luo","year":"2022","unstructured":"Luo Q, Yu XQ, Kahn C, Egger S, Patel MI, Grogan PB et al (2022) Changes in prostate cancer incidence, mortality and survival in relation to prostate specific antigen testing in New South Wales, Australia. Cancer Epidemiol 78:102159","journal-title":"Cancer Epidemiol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-026-05003-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-026-05003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:18:50Z","timestamp":1782483530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-026-05003-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":32,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["5003"],"URL":"https:\/\/doi.org\/10.1007\/s11255-026-05003-9","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,10]]},"assertion":[{"value":"12 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}